EnteroMedics Inc·4

Feb 10, 4:53 PM ET

EnteroMedics Inc 4

4 · EnteroMedics Inc · Filed Feb 10, 2017

Insider Transaction Report

Form 4
Period: 2017-02-08
Transactions
  • Award

    Director Option (Right to Buy)

    2017-02-08+40,00040,000 total
    Exercise: $7.12From: 2017-02-08Exp: 2027-02-08Common Stock (40,000 underlying)
Holdings
  • Director Option (right to buy)

    Exercise: $27730.50From: 2008-05-06Exp: 2018-05-06Common Stock (1 underlying)
    1
  • Director Option (right to buy)

    Exercise: $3402.00From: 2010-02-10Exp: 2020-02-10Common Stock (11 underlying)
    11
  • Director Option (right to buy)

    Exercise: $2761.50From: 2011-05-05Exp: 2021-05-05Common Stock (9 underlying)
    9
  • Director Option (right to buy)

    Exercise: $924.00From: 2013-05-08Exp: 2023-05-08Common Stock (9 underlying)
    9
  • Director Option (right to buy)

    Exercise: $1932.00From: 2014-05-07Exp: 2024-05-07Common Stock (23 underlying)
    23
  • Director Option (right to buy)

    Exercise: $1176.00From: 2015-05-06Exp: 2025-05-06Common Stock (23 underlying)
    23
  • Director Option (Right to Buy)

    Exercise: $52.50From: 2016-05-04Exp: 2026-05-04Common Stock (42 underlying)
    42
  • Common Stock

    10
  • Director Option (right to buy)

    Exercise: $12159.00From: 2009-05-05Exp: 2019-05-05Common Stock (1 underlying)
    1
  • Director Option (right to buy)

    Exercise: $47008.50From: 2007-04-27Exp: 2017-04-27Common Stock (4 underlying)
    4
  • Director Option (right to buy)

    Exercise: $14490.00From: 2009-05-28Exp: 2019-05-28Common Stock (23 underlying)
    23
  • Director Option (right to buy)

    Exercise: $2646.00From: 2010-05-06Exp: 2020-05-06Common Stock (1 underlying)
    1
  • Director Option (right to buy)

    Exercise: $2908.50From: 2012-05-09Exp: 2022-05-09Common Stock (9 underlying)
    9
  • Director Option (right to buy)

    Exercise: $1176.00From: 2015-06-06Exp: 2025-05-06Common Stock (23 underlying)
    23
Footnotes (4)
  • [F1]On December 27, 2016, EnteroMedics Inc. effected a 1-for-70 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person. all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.
  • [F2]Fully vested.
  • [F3]Vests immediately as to 25% on date noted and thereafter in cumulative installments of 1/36th per month.
  • [F4]Vests in cumulative installments of 1/12th per month beginning the date shown.

Documents

2 files
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION

  • EX-24.4_700816

    POA DOCUMENT